Amikacin pharmacokinetic/pharmacodynamic in intensive care unit: a prospective database
Abstract Background Aminoglycosides have a concentration-dependent therapeutic effect when peak serum concentration (C max) reaches eight to tenfold the minimal inhibitory concentration (MIC). With an amikacin MIC of 8 mg/L, the C max should be 64–80 mg/L. This objective is based on clinical breakpo...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
SpringerOpen
2020-06-01
|
Series: | Annals of Intensive Care |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13613-020-00685-5 |
id |
doaj-4cd191e0d23f43d994ede0cc398675f7 |
---|---|
record_format |
Article |
spelling |
doaj-4cd191e0d23f43d994ede0cc398675f72020-11-25T03:20:56ZengSpringerOpenAnnals of Intensive Care2110-58202020-06-011011810.1186/s13613-020-00685-5Amikacin pharmacokinetic/pharmacodynamic in intensive care unit: a prospective databaseElsa Logre0Maya Enser1Sébastien Tanaka2Marie Dubert3Aurore Claudinon4Nathalie Grall5Hervé Mentec6Philippe Montravers7Olivier Pajot8CH Argenteuil, réanimation polyvalenteCH Argenteuil, réanimation polyvalenteCHU Bichat, réanimation chirurgicaleCHU Bichat, maladies infectieuses et tropicalesCH Argenteuil, microbiologieCHU Bichat, microbiologieCH Argenteuil, réanimation polyvalenteCHU Bichat, réanimation chirurgicaleCH Argenteuil, réanimation polyvalenteAbstract Background Aminoglycosides have a concentration-dependent therapeutic effect when peak serum concentration (C max) reaches eight to tenfold the minimal inhibitory concentration (MIC). With an amikacin MIC of 8 mg/L, the C max should be 64–80 mg/L. This objective is based on clinical breakpoints and not on measured MIC. This study aimed to assess the proportion of patients achieving the pharmacokinetic/pharmacodynamic (PK/PD) target C max/MIC ≥ 8 using the measured MIC in critically ill patients treated for documented Gram-negative bacilli (GNB) infections. Methods Retrospective analysis from February 2016 to December 2017 of a prospective database conducted in 2 intensive care units (ICU). All patients with documented severe GNB infections treated with amikacin (single daily dose of 25 mg/kg of total body weight (TBW)) with both MIC and C max measurements at first day of treatment (D1) were included. Results are expressed in n (%) or median [min–max]. Results 93 patients with 98 GNB-documented infections were included. The median C max was 55.2 mg/L [12.2–165.7] and the median MIC was 2 mg/L [0.19–16]. C max/MIC ratio ≥ 8 was achieved in 87 patients (88.8%) while a C max ≥ 64 mg/L was achieved in only 38 patients (38.7%). Overall probability of PK/PD target attainment was 93%. No correlation was found between C max/MIC ratio and clinical outcome at D8 and D28. Conclusion According to PK/PD parameters observed in our study, single daily dose of amikacin 25 mg/kg of TBW appears to be sufficient in most critically ill patients treated for severe GNB infections.http://link.springer.com/article/10.1186/s13613-020-00685-5PharmacokineticPharmacodynamicAmikacinIntensive care unit |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Elsa Logre Maya Enser Sébastien Tanaka Marie Dubert Aurore Claudinon Nathalie Grall Hervé Mentec Philippe Montravers Olivier Pajot |
spellingShingle |
Elsa Logre Maya Enser Sébastien Tanaka Marie Dubert Aurore Claudinon Nathalie Grall Hervé Mentec Philippe Montravers Olivier Pajot Amikacin pharmacokinetic/pharmacodynamic in intensive care unit: a prospective database Annals of Intensive Care Pharmacokinetic Pharmacodynamic Amikacin Intensive care unit |
author_facet |
Elsa Logre Maya Enser Sébastien Tanaka Marie Dubert Aurore Claudinon Nathalie Grall Hervé Mentec Philippe Montravers Olivier Pajot |
author_sort |
Elsa Logre |
title |
Amikacin pharmacokinetic/pharmacodynamic in intensive care unit: a prospective database |
title_short |
Amikacin pharmacokinetic/pharmacodynamic in intensive care unit: a prospective database |
title_full |
Amikacin pharmacokinetic/pharmacodynamic in intensive care unit: a prospective database |
title_fullStr |
Amikacin pharmacokinetic/pharmacodynamic in intensive care unit: a prospective database |
title_full_unstemmed |
Amikacin pharmacokinetic/pharmacodynamic in intensive care unit: a prospective database |
title_sort |
amikacin pharmacokinetic/pharmacodynamic in intensive care unit: a prospective database |
publisher |
SpringerOpen |
series |
Annals of Intensive Care |
issn |
2110-5820 |
publishDate |
2020-06-01 |
description |
Abstract Background Aminoglycosides have a concentration-dependent therapeutic effect when peak serum concentration (C max) reaches eight to tenfold the minimal inhibitory concentration (MIC). With an amikacin MIC of 8 mg/L, the C max should be 64–80 mg/L. This objective is based on clinical breakpoints and not on measured MIC. This study aimed to assess the proportion of patients achieving the pharmacokinetic/pharmacodynamic (PK/PD) target C max/MIC ≥ 8 using the measured MIC in critically ill patients treated for documented Gram-negative bacilli (GNB) infections. Methods Retrospective analysis from February 2016 to December 2017 of a prospective database conducted in 2 intensive care units (ICU). All patients with documented severe GNB infections treated with amikacin (single daily dose of 25 mg/kg of total body weight (TBW)) with both MIC and C max measurements at first day of treatment (D1) were included. Results are expressed in n (%) or median [min–max]. Results 93 patients with 98 GNB-documented infections were included. The median C max was 55.2 mg/L [12.2–165.7] and the median MIC was 2 mg/L [0.19–16]. C max/MIC ratio ≥ 8 was achieved in 87 patients (88.8%) while a C max ≥ 64 mg/L was achieved in only 38 patients (38.7%). Overall probability of PK/PD target attainment was 93%. No correlation was found between C max/MIC ratio and clinical outcome at D8 and D28. Conclusion According to PK/PD parameters observed in our study, single daily dose of amikacin 25 mg/kg of TBW appears to be sufficient in most critically ill patients treated for severe GNB infections. |
topic |
Pharmacokinetic Pharmacodynamic Amikacin Intensive care unit |
url |
http://link.springer.com/article/10.1186/s13613-020-00685-5 |
work_keys_str_mv |
AT elsalogre amikacinpharmacokineticpharmacodynamicinintensivecareunitaprospectivedatabase AT mayaenser amikacinpharmacokineticpharmacodynamicinintensivecareunitaprospectivedatabase AT sebastientanaka amikacinpharmacokineticpharmacodynamicinintensivecareunitaprospectivedatabase AT mariedubert amikacinpharmacokineticpharmacodynamicinintensivecareunitaprospectivedatabase AT auroreclaudinon amikacinpharmacokineticpharmacodynamicinintensivecareunitaprospectivedatabase AT nathaliegrall amikacinpharmacokineticpharmacodynamicinintensivecareunitaprospectivedatabase AT hervementec amikacinpharmacokineticpharmacodynamicinintensivecareunitaprospectivedatabase AT philippemontravers amikacinpharmacokineticpharmacodynamicinintensivecareunitaprospectivedatabase AT olivierpajot amikacinpharmacokineticpharmacodynamicinintensivecareunitaprospectivedatabase |
_version_ |
1724615619713695744 |